Madopar Hbs

Levodopa and benserazide hydrochloride, the active ingredient in Madopar Hbs, is a dopamine precursor and dopa decarboxylase inhibitor presented as an oral tablet for oral use. It is employed to restore dopaminergic activity in patients with Parkinson's disease. The combination enhances central dopamine levels while limiting peripheral conversion, helping to manage motor symptoms such as rigidity, tremor, and bradykinesia.

GNH USA supplies Madopar Hbs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar Hbs, containing levodopa and benserazide, is used in the dopaminergic pathway to treat Parkinson's disease.

- Parkinson's disease (early stage): improves motor control and reduces rigidity. - Parkinson's disease (advanced stage): reduces motor fluctuations and dyskinesia when combined with other agents. - Parkinsonian syndrome secondary to other causes: alleviates dopaminergic deficiency symptoms.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Headache: transient and usually resolves. - Insomnia: difficulty initiating sleep. - Orthostatic hypotension: drop in blood pressure upon standing. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Dyskinesia: involuntary movements, especially at higher doses. - Hallucinations: visual or auditory disturbances. - Severe hypotension: marked blood pressure decline requiring medical attention. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Cardiac arrhythmias: irregular heart rhythms. - Anaphylaxis: severe allergic reaction requiring immediate care.

When prescribing Madopar Hbs, clinicians should consider several safety measures.

- Monitor blood pressure: watch for orthostatic hypotension, especially after dose initiation. - Assess hepatic and renal function: adjust therapy if significant impairment is present. - Review psychiatric history: patients with prior psychosis may develop hallucinations. - Avoid abrupt discontinuation: sudden stop can worsen Parkinsonian symptoms. - Store at room temperature: keep in the original pack, protect from moisture.

Madopar Hbs may interact with several medicines; awareness helps prevent adverse events.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Selective MAO‑B inhibitors (e.g., selegiline) without washout: severe hypertension. - Antipsychotics (e.g., haloperidol): antagonize dopamine effect, reducing efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect, monitor blood pressure. - SSRIs/SNRIs: may increase risk of serotonin syndrome. - Iron supplements: reduce levodopa absorption; separate dosing by at least 2 hours.